1. Home
  2. Blog
  3. UPSC

NexCAR19 Therapy


Why is it in the news?

  • NexCAR19 is India’s first indigenously-developed CAR-T cell therapy developed by ImmunoACT, incubated at IIT Bombay.
  • It was recently authorized by the Central Drugs Standard Control Organisation (CDSCO).

 

About CAR-T Cell Therapy

  • CAR T-cell therapies are a major breakthrough in cancer treatment.
  • Unlike chemotherapy or immunotherapy which involve taking drugs, CAR T-cell therapies use a patient’s own cells. They are modified in the laboratory to activate T-cells and target tumor cells.
  • CAR T-cell therapy has been approved for leukaemias (cancers arising from the cells that produce white blood cells) and lymphomas (arising from the lymphatic system).
  • Other treatments like chemotherapy might extend life by months or years. However, CAR-T therapy aims for a cure and lifelong benefit.
  • CAR-T offers a one-time transformative treatment, especially beneficial for non-responsive cancer patients.
  • The therapy also results in minimal Cytokine Release Syndrome (CRS), which is characterized by inflammation and hyperinflammation in the body due to the death of a significant number of tumor cells, as CAR-T cells are designed to target and eliminate cancer cells.

 

About NexCAR19

  • NexCar19 is a type of CAR-T and gene therapy developed indigenously in India.
  • It is designed to target cancer cells that carry the CD19 protein. This protein acts like a flag on cancer cells, which allows CAR-T cells to recognize and attach themselves to the cancer cells and start the process of elimination.
  • Even some developed nations don’t have their own CAR-T therapies; they import them from the United States or Europe. India is now one of the first developing countries to have its indigenous CAR-T and gene therapy platform.

 

Eligibility for NexCAR19

  • Targets patients with B-cell lymphomas unresponsive to standard treatments.
  • Process: Doctor’s prescription -> Blood donation -> Genetically modification in the lab -> Reinfusion in 7-10 days.
  • Post-treatment recovery in approximately two weeks.
  • About 70% patients respond and 50% of these achieve a complete response.

 

Child Patients

  • B-cell leukaemia is common among children.
  • Paediatric trial phase is currently underway at Tata Memorial Hospital.
  • It is currently approved for patients aged 15 years and older.

 

Availability in India

  • Licensing and hospital onboarding is in progress.
  • Partnered with major hospitals like Tata Hospital, Nanavati, Fortis, and others.
  • Estimated cost is about Rs 30-40 lakh. The goal is to reduce it to Rs 10-20 lakh as technology and processes mature.
  • Typically, therapies approved by agencies like CDSCO should be covered by insurance and given the high cost, coverage specifics might vary.

Get free UPSC Updates straight to your inbox!

Get Updates on New Notification about APPSC, TSPSC and UPSC

Get Current Affairs Updates Directly into your Inbox

Discover more from AMIGOS IAS

Subscribe now to keep reading and get access to the full archive.

Continue reading

WhatsApp Us

Exit mobile version